-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Extranodal NK/T cell lymphoma (ENKTCL) is a rare invasive, non-Hodgkin lymphoma that originates from NK cells and T lymphocytes and is highly aggressive, rapid progression, and poor
Research Methods
Patients included in the study were adult patients
Figure 1 Study design
Results of the study
Patient baseline features
As of 15 February 2022, a total of 31 patients were enrolled (Phase I: 21, Phase II: 10).
Table 1 Patient baseline features
security
All 31 patients experienced "treatment-phase" adverse events (TEAE), and 87.
Figure 2 TEAE occurred in 31 patients
PK result
The PK profile of PLM60 did not change
Table 2 PK results (left: total mitoxantrone; Right: Free mitoxantraquinone ( )
efficacy
Efficacy was assessed in all 31 patients, with a complete response (CR) rate of 61.
Table 3 Efficacy results
Figure 3 Results of efficacy in patients treated at the beginning
Conclusion of the studyPLM60 has good PK characteristics, and the PK characteristics are not affected
after combination with pementlease.
The PLM60+ pementlease protocol has shown significant efficacy and manageable safety
in patients with initial treatment of ENKTCL.
Huang, et al.
2022ESMO.
Abstract #625MO.
Edit: Wenting Review: Mia Typesetting: Wenting Execution: moly
Poke "Read the original article" to see more
